Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer
- Published on 03/11/2025
- Reading time: 5 min.
Wang Yanrong 1,2,3, Jia Ru 3, Si Haiyan 3, Ma Yue 1,2, Fan Mengjiao 1,2, Zhang Nan 1,2, Liu Fangfang 3, Shi Yue 3, Jia Yushan 3, Zhang Yaoyue 3, Han Quanli 2, Wang Zhikuan 3, Dai Guanghai 3
1 https://ror.org/05tf9r976 Medical School of Chinese PLA Beijing China
2 https://ror.org/05tf9r976 Department of Medical Oncology, The First Medical Center Chinese People’s Liberation Army General Hospital 100853 Beijing China
3 https://ror.org/04gw3ra78 Department of Oncology The Fifth Medical Center of PLA General Hospital 100071 Beijing China
Abstract
Background This research aimed to assess the efficacy and safety of combining sintilimab with bevacizumab, oxaliplatin, and capecitabine as a primary therapy for patients with RAS-mutated, microsatellite stable (MSS), and metastatic colorectal cancer (mCRC).
Methods In this prospective, open-label, single-arm, phase II trial, eligible patients received up to 8 cycles of capecitabine and oxaliplatin/bevacizumab plus sintilimab, followed by maintenance therapy...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Oncology
Receive our newsletter to stay up to date with the latest news in Oncology
